Parion Sciences

Focus: Parion Sciences is a Durham, NC-based biotechnology company focused on mucosal targets and respiratory/ocular/oral diseases. The company operates at early clinical stage with a pipeline spanning Phase 1-2 programs.

Unknown

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Open Jobs

About Parion Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow Parion Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

tPAD Device

Lung Diseases

N/A

Clinical Trials (1)

NCT03185650Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device

N/A

Help build intelligence for Parion Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with multiple shots on goal across cystic fibrosis, dry eye disease, and Sjögren's syndrome—exposure to multiple indications reduces single-program risk
Focused platform approach on mucosal targets provides technical differentiation and specialized expertise-building opportunity
Pre-revenue biotech at Phase 1-2 stage offers potential equity upside for early-stage employees

Watch Out For

Minimal public hiring activity (1 active role) signals constrained headcount growth and limited near-term career mobility
No Phase 3 programs and only 8 active trials suggest extended timeline to value creation—clinical-stage risk is substantial
Complete absence of financial data (revenue, funding, cash position) raises questions about runway and investor confidence

Generated by Claude from Parion Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

inhaled hypertonic saline

Cystic Fibrosis

Phase 1

Clinical Trials (1)

NCT02141191A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

Phase 1

P-321 Ophthalmic Solution

Dry Eye Disease

Phase 1

Clinical Trials (1)

NCT02242032Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Phase 1